SERES THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.005 USD | -1.47% |
|
-13.44% | -26.42% |
| 09/05 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
| 09/05 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SERES THERAPEUTICS, INC. | Bio Therapeutic Drugs | +0.49% | -13.44% | -26.42% | -80.67% | -75.82% | 154M |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- MCRB Stock
- Charts Seres Therapeutics, Inc.
- Comparison Chart
